Searchable abstracts of presentations at key conferences in endocrinology

ea0013p189 | Diabetes, metabolism and cardiovascular | SFEBES2007

Quality of life in women attending a patient-centred, nurse-led endocrine clinic for management of polycystic ovary syndrome

Percy Carol , Gibbs Tineke , Boardman Shirine , Todkill Dan

Objective: The objective was to assess the impact of polycystic ovary syndrome (PCOS) on the quality of life of in women attending a patient-centred, nurse-led endocrine clinic.Method: An audit was conducted of quality of life data for N=152 women attending the clinic for management of PCOS. While one important focus of the clinic is weight management, not all these patients were overweight or obese (weight range 44.7–159.6 kg, mean weight 89...

ea0013p190 | Diabetes, metabolism and cardiovascular | SFEBES2007

Quality of life in polycystic ovary syndrome: Positive changes in women attending a patient-centred, nurse-led endocrine clinic

Percy Carol , Gibbs Tineke , Boardman Shirine , Todkill Dan

Objective: The objective was to assess the impact of polycystic ovary syndrome (PCOS) on the quality of life of women attending a patient-centred, nurse-led endocrine clinic, and to investigate changes in quality of life over time.Method: Women attending the clinic, for management of PCOS, completed the PCOSQ (Cronin et al. 1998) at their first appointment. The PCOSQ is the only validated quality of life measure specifically focused on PCOS. It as...

ea0015oc21 | Tumours, diabetes, bone | SFEBES2008

Delineating the mechanisms of Visfatin regulation in human AT and the implications of TZD treatment in Type 2 Diabetes

McGee Kirsty , Harte Alison , da Silva Nancy , Creely Steven , Baker Adam , Kusminski Christine , Khanolkar Manish , Evans Marc , Chittari Madhu , Patel Vinod , Boardman Shirine , Kumar Sudhesh , McTernan Philip

Objective: The adipocytokine visfatin, expressed in abdominal adipose tissue (AT) is thought to mimic insulin activity. However, whilst central adiposity is closely related to insulin resistance (IR) and T2DM, visfatinsÂ’ role in the development of these conditions remains unclear.Method: We investigated circulating visfatin levels in non-diabetic (ND) and diabetic (T2DM) subjects and in T2DM patients pre- and post- rosiglitazone (RSG) treatment. We ...